SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.

"R. L. Avery reports grants and nonfinancial support from Genentech, Inc, during the conduct of the study; grants, personal fees, and nonfinancial support from Genentech, Inc; personal fees from Iridex; personal fees from Alcon; grants and personal fees from Allergan; personal fees from Alimera; grants, personal fees, and nonfinancial support from Regeneron; personal fees and nonfinancial support from Replenish; grants and personal fees from Ophthotech; personal fees and nonfinancial support from Novartis; personal fees from Johnson and Johnson; grants and personal fees from QLT; and personal fees from Bausch and Lomb outside the submitted work. In addition, R. L. Avery has a patent Intravitreal Drug Delivery licensed to Replenish. D. J. Pieramici reports grants and nonfinancial support from Genentech, Inc, during the conduct of the study; grants and personal fees from Genentech, Inc; grants and personal fees from Allergan; personal fees from Santen; and personal fees from Alimera outside the submitted work. N. C. Steinle reports grants and nonfinancial support from Genentech, Inc during the conduct of the study; personal fees from Regeneron; and research funding from Zeiss outside the submitted work. A. A. Castellarin reports grants and nonfinancial support from Genentech, Inc, during the conduct of the study; grants and personal fees from Genentech, Inc; and consulting fees from Allergan and Alimera outside the submitted work. S. Couvillion reports grants and nonfinancial support from Genentech, Inc, during the conduct of the study; grants and personal fees from Genentech, Inc, outside the submitted work. R. See and M. A. Nasir report grants and nonfinancial support from Genentech, Inc, during the conduct of the study. D. S. Dhoot reports grants and nonfinancial support from Genentech, Inc, during the conduct of the study and speaker and research grants from Regeneron outside the submitted work. M. D. Rabena reports grants and nonfinancial support from Genentech, Inc, during the conduct of the study. He was an employee of California Retina Consultants when the study was conducted and is currently an employee of Genentech, Inc. S. Van Everen was an employee of Genentech, Inc, at the time the study was conducted and is currently an employee of REGENEXBIO. W. D. Hanley and M. Maia are employees of Genentech, Inc. K. Le was an employee of Genentech, Inc, at the time of the study and is currently an employee of Agios Pharmaceuticals."

"Supported by Genentech, Inc, and California Retina Research Foundation, Santa Barbara, CA. These sponsors participated in the design and conduct of the studies; data collection, analysis, and interpretation of results; and preparation, review, and approval of the manuscript."

"The study protocol was Institutional Review Board approved and was conducted in accordance with U.S. Food and Drug Administration Good Clinical Practice guidelines. Written informed consent was provided by all patients for study participation. This study was Health Insurance Portability and Accountability Act compliant and adhered to the tenets of the declaration of Helsinki. This study is registered at clinicaltrials.gov (NCT02118831)."